Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 266

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 266
---
 31, 2024                                                                                                                                     
 for Mr. Garland was 600,000, none of which were vested. 25% of each of the option awards vests upon the first anniversary of the grant date, and the remainder vests and becomes exercisable in thirty-six (36) substantially equal monthly 
 installments thereafter.                                                                                                                                                                                                                    |

| (4) | The aggregate number of shares issuable upon exercise of option awards outstanding at December 31, 2024                                                                                                                                          
 for Dr. Ruffolo, Jr. was 370,000, 70,000 of which were fully vested. 25% of the option awards vests upon the first anniversary of the grant date, and the remainder vests and becomes exercisable in thirty-six (36) substantially equal monthly 
 installments thereafter.                                                                                                                                                                                                                         |

Ms. Turner, our current Chief Executive Officer, and Mr. Prensky, our former Chief Executive Officer, each of whom is also a director, did not receive any additional compensation for their respective service as directors in 2024. Ms. Turner and Mr. Prensky’s compensation as named executive officers in 2024 is set forth below under “Executive Compensation—Summary Compensation Table.” Non-EmployeeDirector Compensation Policy We intend to adopt a formal non-employee directorcompensation policy in connection with this offering and on terms to be determined by our board of directors. Under the non-employee directorpolicy, our non-employee directorswill be eligible to receive compensation for service on our board of directors and committees of our board of directors. 183

EXECUTIVE COMPENSATION Our named executive officers for the year ended December 31, 2024, consisting of the two individuals who served as our principal executive officer during the fiscal year ended December 31, 2024 and the next two most highly compensated executive officers who were serving in such capacity as of December 31, 2024, were:

| • |     | Heather Turner, our Chief Executive Officer and a member of our board of directors; |

| • |     | Zachary Prensky, our former Chief Executive Officer and a member of our board of directors; |

| • |     | Roger Sawhney, our former Chief Financial Officer; and |

| • |     | Anna Eramo, M.D., our Chief Medical Officer. |

Summary Compensation Table The following table sets forth information regarding all of the compensation awarded to or earned by or paid to our named executive officers during the fiscal year ended December 31, 202